Intranasal hypocretin-1: Making sense of scents?

Sleep Medicine

Volumn 12, Issue 10, 2011, Pages 939-940

  Lammers, Gert Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

DRUG EFFECT; FEMALE; HUMAN; MALE; NARCOLEPSY; NOTE; REM SLEEP; WAKEFULNESS;

FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NARCOLEPSY; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; SLEEP, REM; WAKEFULNESS;

MLCS; MLOWN;

EID: 84859907507     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.11.002     Document Type: Editorial

References (19)

1. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:3 (1999), 365–376.
2. Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammell, T., Lee, C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:4 (1999), 437–451.
3. Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charnay, Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:9 (2000), 991–997.
4. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., Mignot, E., Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:9197 (2000), 39–40.
5. Baier PC, Hallschmid M, Seeck-Hirschner M, Weinhold SL, Burkert S, Diessner N, Göder R, et al. Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med, in press.
6. Kastin, A.J., Akerstrom, V., Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 289:1 (1999), 219–223.
7. Kodama, T., Kimura, M., Arousal effects of orexin-A correlate with GLU release from the locus coeruleus in rats. Peptides 23:9 (2002), 1673–1681.
8. John, J., Wu, M.F., Siegel, J.M., Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 3:1 (2000), 23–28.
9. Fujiki, N., Yoshida, Y., Ripley, B., Mignot, E., Nishino, S., Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26:8 (2003), 953–959.
10. Hanson, L.R., Martinez, P.M., Taheri, S., Kamsheh, L., Mignot, E., Frey, W.H. 2nd, Intranasal administration of hypocretin-1 (orexin-A) bypasses the blood-brain barrier and targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Technol(4), 2004, 66–71.
11. Dhuria, S.V., Hanson, L.R., Frey, W.H. 2nd, Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 98:7 (2009), 2501–2515.
12. Deadwyler, S.A., Porrino, L., Siegel, J.M., Hampson, R.E., Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27:52 (2007), 14239–14247.
13. Baier, P.C., Weinhold, S.L., Huth, V., Gottwald, B., Ferstl, R., Hinze-Selch, D., Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 131:Pt 10 (2008), 2734–2741.
14. Piper, D.C., Upton, N., Smith, M.I., Hunter, A.J., The novel brain neuropeptide, orexin-A, modulates the sleep–wake cycle of rats. Eur J Neurosci 12:2 (2000), 726–730.
15. Overeem, S., Mignot, E., van Dijk, J.G., Lammers, G.J., Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:2 (2001), 78–105.
16. Scammell, T.E., Winrow, C.J., Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51 (2011), 243–266.
17. Fronczek, R., Overeem, S., Lee, S.Y., Hegeman, I.M., van Pelt, J., van Duinen, S.G., et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's disease. Brain 130:Pt. 6 (2007), 1577–1585.
18. Thannickal, T.C., Lai, Y.Y., Siegel, J.M., Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130:Pt. 6 (2007), 1586–1595.
19. Friedman, L.F., Zeitzer, J.M., Lin, L., Hoff, D., Mignot, E., Peskind, E.R., et al. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68:10 (2007), 793–794.